Your browser doesn't support javascript.
loading
Synergistic effect of human uterine cervical mesenchymal stem cell secretome and paclitaxel on triple negative breast cancer.
Eiro, Noemi; Fraile, Maria; Escudero-Cernuda, Sara; Sendon-Lago, Juan; Gonzalez, Luis O; Fernandez-Sánchez, Maria Luisa; Vizoso, Francisco J.
Afiliación
  • Eiro N; Research Unit, Hospital de Jove Foundation, Gijón, Spain. noemi.eiro@hospitaldejove.com.
  • Fraile M; Research Unit, Hospital de Jove Foundation, Gijón, Spain.
  • Escudero-Cernuda S; Department of Physical and Analytical Chemistry, University of Oviedo, Oviedo, Spain.
  • Sendon-Lago J; Experimental Biomedicine Centre (CEBEGA), University of Santiago de Compostela, Santiago de Compostela, Spain.
  • Gonzalez LO; Research Unit, Hospital de Jove Foundation, Gijón, Spain.
  • Fernandez-Sánchez ML; Department of Physical and Analytical Chemistry, University of Oviedo, Oviedo, Spain.
  • Vizoso FJ; Research Unit, Hospital de Jove Foundation, Gijón, Spain. investigacion@hospitaldejove.com.
Stem Cell Res Ther ; 15(1): 121, 2024 Apr 25.
Article en En | MEDLINE | ID: mdl-38664697
ABSTRACT

BACKGROUND:

Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer and, despite its adverse effects, chemotherapy is the standard systemic treatment option for TNBC. Since, it is of utmost importance to consider the combination of different agents to achieve greater efficacy and curability potential, MSC secretome is a possible innovative alternative.

METHODS:

In the present study, we proposed to investigate the anti-tumor effect of the combination of a chemical agent (paclitaxel) with a complex biological product, secretome derived from human Uterine Cervical Stem cells (CM-hUCESC) in TNBC.

RESULTS:

The combination of paclitaxel and CM-hUCESC decreased cell proliferation and invasiveness of tumor cells and induced apoptosis in vitro (MDA-MB-231 and/or primary tumor cells). The anti-tumor effect was confirmed in a mouse tumor xenograft model showing that the combination of both products has a significant effect in reducing tumor growth. Also, pre-conditioning hUCESC with a sub-lethal dose of paclitaxel enhances the effect of its secretome and in combination with paclitaxel reduced significantly tumor growth and even allows to diminish the dose of paclitaxel in vivo. This effect is in part due to the action of extracellular vesicles (EVs) derived from CM-hUCESC and soluble factors, such as TIMP-1 and - 2.

CONCLUSIONS:

In conclusion, our data demonstrate the synergistic effect of the combination of CM-hUCESC with paclitaxel on TNBC and opens an opportunity to reduce the dose of the chemotherapeutic agents, which may decrease chemotherapy-related toxicity.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Paclitaxel / Proliferación Celular / Células Madre Mesenquimatosas / Neoplasias de la Mama Triple Negativas / Secretoma Límite: Animals / Female / Humans Idioma: En Revista: Stem Cell Res Ther Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Paclitaxel / Proliferación Celular / Células Madre Mesenquimatosas / Neoplasias de la Mama Triple Negativas / Secretoma Límite: Animals / Female / Humans Idioma: En Revista: Stem Cell Res Ther Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido